Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community.
about
Clinical adoption of prognostic biomarkers: the case for heart failureLipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study.Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker.Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease.Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.
P2860
Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Plasma lipoprotein-associated ...... th mortality in the community.
@en
Plasma lipoprotein-associated ...... th mortality in the community.
@nl
type
label
Plasma lipoprotein-associated ...... th mortality in the community.
@en
Plasma lipoprotein-associated ...... th mortality in the community.
@nl
prefLabel
Plasma lipoprotein-associated ...... th mortality in the community.
@en
Plasma lipoprotein-associated ...... th mortality in the community.
@nl
P2093
P2860
P1433
P1476
Plasma lipoprotein-associated ...... th mortality in the community.
@en
P2093
Allan S Jaffe
Jill M Killian
Joseph P McConnell
Shannon M Dunlay
Susan A Weston
Véronique L Roger
Yariv Gerber
P2860
P304
P356
10.1016/J.ATHEROSCLEROSIS.2008.07.035
P577
2008-08-07T00:00:00Z